News & Events

GluBio Announced Positive Preliminary Phase I Results for GLB-002 at the 2025 ASH Annual Meeting

Successful Completion of Dose Escalation at the First Dose Level in the Ongoing Phase 1 Trial of GLB-002 in Patients with R/R NHL

GLB-001, China’s First Selective CK1α Molecular Glue Protein Degrader, Approved for Clinical Trials

GluBio Presented an Oral Report on Preclinical Data of a First-in-Class WIZ Molecular Glue Degrader at the Second Molecular Glue Drug Development Summit

GLB-002, A Novel Molecular Glue Degrader, Approved for Clinical Trials